Merck: Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years Tumor responses remained…